Novartis wins expanded GIST use for Gleevec; Takeda cuts outlook as Astellas forecasts growth;

@FiercePharma: Pfizer recalls 1 million birth control packets b/c the active-pill count could be wrong, risking pregnancy. News | Follow @FiercePharma

> Novartis ($NVS) won FDA approval for expanded use of its cancer drug Gleevec, for three-year adjuvant treatment of patients with KIT+ gastrointestinal stromal tumors. Release

> Takeda Pharmaceutical cut its earnings outlook on the initial costs of integrating its purchase of the Swiss pharma Nycomed, while fellow Japanese drugmaker Astellas Pharma is predicting new growth. Report

> Novartis ($NVS) CEO Joe Jimenez said volatile currencies present an ongoing risk, so his company is working on ways to lessen the impact of adverse movements, including stepped-up cash collections. More

> Merck ($MRK) is consolidating its animal health headquarters in New Jersey, moving marketing and administrative operations to the area from the Netherlands. About 65 jobs are expected to be lost at one of the company's Dutch sites. Article

> Over-the-counter drugs save the U.S. healthcare system $102 billion per year as consumers spend their own money on remedies rather than relying on prescription drugs that require payer reimbursements and clinical visits, an industry study found. Report

> Teva Pharmaceutical Industries' ($TEVA) choice of a new CEO is not only lifting the drugmaker's shares but underpinning the best new-year performance for Israeli stocks since 1997. News

Biotech News

@FierceBiotech: Check out FierceBiotech's FDA Approvals of 2011 Slideshow. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CFO mulls dividend--eventually. My bet is they want to use their $3B in cash for deals. More | Follow @JohnCFierce

@FierceMedDev: Device Makers Said to Double FDA Fees to Produce Faster Reviews--Bloomberg. Article | Follow @FierceMedDev

@MarkHFierce: How to better detect genes linked to cancer? A liquid laser, it seems. If it is safe for the patient, then why not? Story | Follow @MarkHFierce

> Sanofi trims staff at Genzyme R&D as it builds Boston hub. News

> Gold out, Johnson in as troubled Dendreon aims for a turnaround. Story

Medical Device News

> ConforMis nails $89M for iTotal knee manufacturing + launch. Article

> Roche will nominate Illumina board candidates. Item

> CartiHeal scores $5M ahead of 2013 product launch. Story

Drug Delivery News

> Impax licenses U.S. rights to three versions of AstraZeneca migraine drug. News

> AMT's Glybera, delivered through virus, faces Euro reg delay. More

> Takeda abandons Euro rights to Durect's controlled-release pain drug. Story

> New drug delivery system slows water filtration, displaces air. Article

> Amylin gets FDA OK for weekly diabetes drug Bydureon. News

> Nanotech transforms cyclosporine into safer transplant drug. Item

Biomarkers News

> Alzheimer's biomarkers panel not clear-cut after all. News

> Genetic test could up outcomes after lung cancer surgery. Article

> MRS can detect brain tumor biomarker. Item

> NINDS is close to launching its first NeuroNEXT neurobiomarkers study. Story

> Markers from breast could predict weight loss surgery outcome. More

And Finally... About two-thirds of Pfizer workers affected by the Kent, U.K., site cutbacks have found other jobs, local officials said. Report

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.